Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 23, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 1,100,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,162.0 pence per share; lowest price paid was 1,149.0 pence per share.
- Treasury Shares Held: 493,224,284 shares (8.70% of total issued share capital; 9.53% of total voting rights).
- Shares in Issue: 5,175,216,085 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 1,100,000 repurchased shares. The filing does not provide comparative data against prior periods for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding the share repurchase.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by calculating the weighted average price between 1,149.0 and 1,162.0 pence for the 1,100,000 shares.
- Confirm the updated total issued share capital after the cancellation of the repurchased shares.
- Review the impact of the 8.70% Treasury share holding on future earnings per share (EPS) calculations.
- Check subsequent filings for the total volume of shares repurchased under the May 2010 authorization.